Home
Astrid Børretzen's picture

Astrid Børretzen

Guest Researcher
  • E-mailastrid.borretzen@uib.no
  • Visitor Address
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) (2023). Microvascular proliferation is associated with high tumour blood flow by mpMRI and disease progression in primary prostate cancer. Scientific Reports.
  • Show author(s) (2023). A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer. Cancer Immunology and Immunotherapy.
  • Show author(s) (2022). PRSS2 remodels the tumor microenvironment via repression of Tsp1 to stimulate tumor growth and progression. Nature Communications. 1-19.
  • Show author(s) (2021). The epithelial–mesenchymal transition regulators Twist, Slug, and Snail are associated with aggressive tumour features and poor outcome in prostate cancer patients. The journal of pathology. Clinical research. 253-270.
  • Show author(s) (2019). FOXC2 expression and epithelial–mesenchymal phenotypes are associated with castration resistance, metastasis and survival in prostate cancer. The journal of pathology. Clinical research. 272-286.
Academic lecture
  • Show author(s) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC) .
Short communication
  • Show author(s) (2023). A prospective non-randomized phase I trial of dendritic cell–based cryoimmunotherapy combined with checkpoint inhibitors in mCRPC. Journal of Clinical Oncology.
Abstract
  • Show author(s) (2013). Does GEWF solution improve lymph node harvest in colorectal cancer specimens with and without neoadjuvant therapy? Virchows Archiv. 210-211.
Poster
  • Show author(s) (2023). Survival and biomarkers in a prospective non-randomized phase I trial of dendritic cell-based cryoimmunotherapy combined with checkpoint inhibitors in metastatic castration-resistant prostate cancer (mCRPC).

More information in national current research information system (CRIStin)